Cosmo Bio Company,Limited
Cosmo Bio Company,Limited Fundamental Analysis
Cosmo Bio Company,Limited (3386.T) shows weak financial fundamentals with a PE ratio of 21.28, profit margin of 3.12%, and ROE of 3.68%. The company generates $10.8B in annual revenue with moderate year-over-year growth of 7.46%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 43.5/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 3386.T's fundamental strength across five key dimensions:
Efficiency Score
Weak3386.T struggles to generate sufficient returns from assets.
Valuation Score
Excellent3386.T trades at attractive valuation levels.
Growth Score
Moderate3386.T shows steady but slowing expansion.
Financial Health Score
Excellent3386.T maintains a strong and stable balance sheet.
Profitability Score
Weak3386.T struggles to sustain strong margins.
Key Financial Metrics
Is 3386.T Expensive or Cheap?
P/E Ratio
3386.T trades at 21.28 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 3386.T's PEG of 0.55 indicates potential undervaluation.
Price to Book
The market values Cosmo Bio Company,Limited at 0.76 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 15.69 times EBITDA. This signals the market has high growth expectations.
How Well Does 3386.T Make Money?
Net Profit Margin
For every $100 in sales, Cosmo Bio Company,Limited keeps $3.12 as profit after all expenses.
Operating Margin
Core operations generate 3.19 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $3.68 in profit for every $100 of shareholder equity.
ROA
Cosmo Bio Company,Limited generates $2.65 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Cosmo Bio Company,Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Cosmo Bio Company,Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
3386.T converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
21.28
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.55
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.76
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.66
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.002
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.23
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.04
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How 3386.T Stacks Against Its Sector Peers
| Metric | 3386.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 21.28 | 27.91 | Better (Cheaper) |
| ROE | 3.68% | 687.00% | Weak |
| Net Margin | 3.12% | -45285.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.33 | Strong (Low Leverage) |
| Current Ratio | 5.23 | 2795.76 | Strong Liquidity |
| ROA | 2.65% | -13557.00% (disorted) | Weak |
3386.T outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Cosmo Bio Company,Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
34.79%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
12.68%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-56.83%
Industry Style: Defensive, Growth, Innovation
Declining